Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Study of the Renoprotective Efficacy of Aliskiren in Addition to Angiotensin II Receptor Blocker in Chronic Kidney Disease

NCT01150201 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT01150201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01150201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Study of the Renoprotective Efficacy of Aliskiren in Addition to Angiotensin II Receptor Blocker in Chronic Kidney Disease
Lead sponsor
The University of Hong Kong
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2009
Completion date
August 31, 2014
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney disease